Half-Life Extended Antibody Platform

Our Half-Life Extended Antibody Platform integrates advanced antibody engineering technologies, aiming to optimize the pharmacokinetic properties of antibody drugs, extend antibody half-life, reduce clearance rate, and decrease dosing frequency, thereby improving patient compliance in disease treatment. We have developed a series of antibody drugs using this platform, including MIL116 and other candidates.

The products with half-life extended antibody mechanism can reduce dosing frequency, improve patient compliance, stabilize blood drug concentration, and minimize toxic and side effects, making it particularly suitable for chronic diseases such as diabetes and arthritis.

The core antibody engineering technologies of this platform include: (1) Isoelectric point (pI)/Charge Engineering: By modifying the isoelectric point and charge distribution of antibodies, it regulates the non-specific endocytosis of antibodies, thereby optimizing their metabolic processes in vivo. (2) Enhanced FcRn Binding: By enhancing the binding ability of antibodies to the neonatal Fc receptor (FcRn), it promotes the recycling of antibodies from endosomes back to the plasma, extending the circulatory half-life of antibodies in vivo. (3) pH-Dependent Antigen Dissociation: Utilizing pH changes to achieve the dissociation of antibodies from target antigens, it optimizes the target-mediated drug disposition (TMDD) process and further prolongs the antibody half-life. The integration of these technologies enables us to develop antibody drugs with superior pharmacokinetic properties.